Lucence, in collaboration with DxD Hub and NCCS, has launched UNITED 2.0, a S$6 million initiative aimed at enhancing cancer diagnostics through advanced AI and comprehensive genomic analysis.
This new research collaboration builds on the earlier UNITED 1.0 initiative, which utilized a tissue test to guide treatment decisions for cancer patients since 2021. The upgraded test, UNITED 2.0, will employ dual Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) to provide a more thorough analysis of tumors, identifying complex mutations and genetic fusions that can be targeted by precision therapies. This shift from traditional gene snapshots to a more expansive view of cancer genetics promises to improve treatment personalization.
In addition to expanding the genomic profiling capabilities, the collaboration aims to develop tools for monitoring patients post-treatment, including Minimal Residual Disease (MRD) testing, which can detect early signs of cancer recurrence. This proactive approach is designed to facilitate timely clinical interventions.
Moreover, a Memorandum of Understanding was established between Lucence, the Brain Tumour Society Singapore, and DxD Hub to ensure that patient experiences inform the development of these diagnostic tools. This partnership underscores the importance of integrating patient perspectives into cancer research, emphasizing that accurate diagnosis is crucial for effective treatment.
The UNITED 2.0 initiative is poised to significantly advance the landscape of precision oncology, with the potential to enhance treatment options for patients, particularly those with rare or treatment-resistant cancers. As the collaboration unfolds over the next three years, its focus on patient-centric research and innovative technology may set a new standard for cancer diagnostics.